Hisamitsu Pharmaceutical updates on treasury share acquisition program

Hisamitsu Pharmaceutical Co., Inc. announced on October 3, 2025, the status of its treasury share acquisition for September 2025. During the period from September 1 to September 30, 2025, the company acquired 392,000 shares of its common stock through market purchases on the Tokyo Stock Exchange. The total acquisition cost for this period amounted to JPY 1,672,753,200.

This acquisition falls under the share repurchase program approved by the board of directors on July 10, 2025. The resolution authorized the acquisition of up to 3 million shares, representing 4.09% of outstanding shares (excluding treasury shares), or a maximum of JPY 15 bn, between July 11, 2025, and December 31, 2025.

As of September 30, 2025, Hisamitsu Pharmaceutical has cumulatively acquired 2,314,200 shares under this resolution, with a total acquisition cost of JPY 9,456,020,100. The company utilizes both off-auction transactions (ToSTNeT-3) and open market purchases for these acquisitions.